Richard Görlick

1996–2025 年に発表

別表記
Richard Gorlick
141
論文数
23,299
被引用数
88
h 指数
139
i10 指数

被引用数

Richard Görlick の年別被引用数1986 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 1 件1994 年: 被引用 2 件1996 年: 被引用 2 件1997 年: 被引用 1 件1998 年: 被引用 10 件1999 年: 被引用 25 件2000 年: 被引用 8 件2001 年: 被引用 22 件2002 年: 被引用 38 件2003 年: 被引用 58 件2004 年: 被引用 80 件2005 年: 被引用 103 件2006 年: 被引用 106 件2007 年: 被引用 103 件2008 年: 被引用 134 件2009 年: 被引用 176 件2010 年: 被引用 178 件2011 年: 被引用 157 件2012 年: 被引用 157 件2013 年: 被引用 162 件2014 年: 被引用 138 件2015 年: 被引用 181 件2016 年: 被引用 167 件2017 年: 被引用 161 件2018 年: 被引用 140 件2019 年: 被引用 736 件2020 年: 被引用 867 件2021 年: 被引用 840 件2022 年: 被引用 702 件2023 年: 被引用 559 件2024 年: 被引用 891 件2025 年: 被引用 436 件2026 年: 被引用 7 件1987〜1991 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,843 件、この内訳の 26.5%中国: 引用元論文 1,562 件、この内訳の 22.4%イギリス: 引用元論文 349 件、この内訳の 5%ドイツ: 引用元論文 311 件、この内訳の 4.5%イタリア: 引用元論文 304 件、この内訳の 4.4%フランス: 引用元論文 249 件、この内訳の 3.6%カナダ: 引用元論文 210 件、この内訳の 3%オーストラリア: 引用元論文 202 件、この内訳の 2.9%日本: 引用元論文 169 件、この内訳の 2.4%オランダ: 引用元論文 166 件、この内訳の 2.4%スペイン: 引用元論文 151 件、この内訳の 2.2%スイス: 引用元論文 112 件、この内訳の 1.6%
0%26.5%その他 19.1%

分野

  • Medicine54%
  • Biochemistry, Genetics and Molecular Biology34.9%
  • Immunology and Microbiology3.8%
  • Engineering3.1%
  • Materials Science1%
  • Computer Science0.7%
  • その他2.5%

トピック

  • Sarcoma Diagnosis and Treatment9.1%
  • Cancer-related molecular mechanisms research2.9%
  • MicroRNA in disease regulation2.5%
  • Neuroblastoma Research and Treatments2.5%
  • CAR-T cell therapy research2.2%
  • Bone Tumor Diagnosis and Treatments2.1%
  • その他78.7%

共著者

全論文

検索で開く
  1. Advancing therapy for osteosarcoma

    著者: , - Nature Reviews Clinical Oncology 2021 被引用: 874

  2. Osteosarcoma

    著者: , , , , , , , , , - Nature Reviews Disease Primers 2022 被引用: 595

  3. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

    著者: , , , - Journal of Clinical Oncology 2015 被引用: 1,604

  4. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Kühne, Leo Kager, Thekla von Kalle, Edita Kabíčková, Susanna Lang, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Regine Mayer‐Steinacker, Paul A. Meyers, Raj Nagarajan, R. Lor Randall, Peter Reichardt, Marleen Renard, Catherine Rechnitzer, Cindy L. Schwartz, Sandra J. Strauss, Lisa A. Teot, Beate Timmermann, Matthew R. Sydes, Neyssa Marina - European Journal of Cancer 2019 被引用: 726

  5. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katherine A. Janeway, Heribert Jürgens, Leo Kager, Thomas Kühne, Ching C. Lau, Patrick J. Leavey, Stephen L. Lessnick, Leo Mascarenhas, Paul A. Meyers, Hubert Mottl, Michaela Nathrath, Zsuzsanna Pápai, R. Lor Randall, Peter Reichardt, Marleen Renard, Akmal Safwat, Cindy L. Schwartz, Michaël C.G. Stevens, Sandra J. Strauss, Lisa A. Teot, Mathias Werner, Matthew R. Sydes, Jeremy Whelan - The Lancet Oncology 2016 被引用: 541

  6. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paula J. Schomberg, Per‐Ulf Tunn, Thomas Kühne, Heribert Jürgens, Henk van den Berg, Tom Böhling, Susan Picton, Marleen Renard, Peter Reichardt, Joachim Gerß, Trude Butterfaß‐Bahloul, Carol D. Morris, Pancras C.W. Hogendoorn, Beatrice Seddon, Gabriele Calaminus, Maria Michelagnoli, Catharina Dhooge, Matthew R. Sydes, Mark L. Bernstein - Journal of Clinical Oncology 2015 被引用: 421

  7. Current and future therapeutic approaches for osteosarcoma

    著者: , , , , - Expert Review of Anticancer Therapy 2017 被引用: 715

  8. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nilgün Kurucu, İlhan İnci, Mandy L. Ballinger, David M. Thomas, Donald A. Barkauskas, Gerardo Mejia-Baltodano, Patricia Valverde, Belynda Hicks, Bin Zhu, Mingyi Wang, Amy Hutchinson, Margaret A. Tucker, Joshua N. Sampson, Maria Teresa Landi, Neal D. Freedman, Susan M. Gapstur, Brian S. Carter, Robert N. Hoover, Stephen J. Chanock, Sharon A. Savage - JAMA Oncology 2020 被引用: 252

  9. The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

    著者: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 122

  10. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 193

  11. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines

    著者: , , , , , , - Frontiers in Immunology 2022 被引用: 89

  12. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

    著者: , , , , , , , , , , , , , , , , , , , , - British Journal of Cancer 2018 被引用: 137

  13. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yunchen Du, Huiyuan Zhang, Holly Lindsay, Sibo Zhao, Jack Shu, Patricia Baxter, Christopher L. Morton, Dias Kurmashev, Siyuan Zheng, Yidong Chen, Jay Bowen, Anthony C. Bryan, Kristen Leraas, Sara E. Coppens, HarshaVardhan Doddapaneni, Zeineen Momin, Wendong Zhang, Gregory I. Sacks, Lori S. Hart, Kateryna Krytska, Yaël P. Mossé, Gregory J. Gatto, Yolanda Sánchez, Casey S. Greene, Sharon J. Diskin, Olena M. Vaske, David Haussler, Julie M. Gastier‐Foster, E. Anders Kolb, Richard Görlick, Xiao-Nan Li, C. Patrick Reynolds, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock, Pichai Raman, David A. Wheeler, John M. Maris - Cell Reports 2019 被引用: 173

  14. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 87

  15. Chemotherapy resistance in osteosarcoma: current challenges and future directions

    著者: , - Expert Review of Anticancer Therapy 2006 被引用: 381

  16. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 250

  17. Children's Oncology Group's 2013 blueprint for research: Bone tumors

    著者: , , , , - Pediatric Blood & Cancer 2012 被引用: 234

  18. Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

    著者: , , , , , , , , , , , , , - European Journal of Cancer 2019 被引用: 78

  19. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Neyssa Marina, Bruce Morland, Hélène Pacquement, Michael Paulussen, R. Lor Randall, Andreas Ranft, Gwénaël Le Teuff, Keith Wheatley, Jeremy Whelan, Richard B. Womer, Odile Oberlin, Douglas S. Hawkins, on behalf of the Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators - Journal of Clinical Oncology 2019 被引用: 145

  20. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors

    著者: , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 52

  21. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul A. Meyers, Carol D. Morris, Hubert Mottl, Helen Nadel, Rajaram Nagarajan, R. Lor Randall, Paula J. Schomberg, R. Schwarz, Lisa A. Teot, Matthew R. Sydes, Mark L. Bernstein, James D. Pickering, Nicola Joffe, Matthias Kevric, Benjamin Sorg, Doojduen Villaluna, Caroline Wang, Martha Perisoglou, Leonardo Trani, Jenny Potratz, D. Carrle, Miriam Wilhelm, Katja Zils, C. Teske - Annals of Oncology 2014 被引用: 333

  22. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models

    著者: , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2024 被引用: 36

  23. Future directions in the treatment of osteosarcoma

    著者: , , - Current Opinion in Pediatrics 2015 被引用: 273

  24. Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma

    著者: , , , , , , , - Cancer 2013 被引用: 158